SCHEMBL25323396

SCHEMBL25323396

COc1nc(C(F)(F)F)cnc1Br

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.35
S100A9 P06702 1/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
AURKA O14965 1/20 0.33
KDR P35968 1/20 0.33
AURKB Q96GD4 1/20 0.33
GAA P10253 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MBOAT4 Q96T53 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
LRRK2 Q5S007 1/20 0.31
GABRA1 P14867 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31
GABRA3 P34903 1/20 0.31
CCR4 P51679 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31365793 1.00 ULK1 (0.35) ULK1S100A9KDM4EALDH1A1L3MBTL1
SCHEMBL25325014 0.78 KDM4E (0.36) KDM4EAURKAKDRAURKBGAA
SCHEMBL24457886 0.76 AURKA (0.36) S100A9KDM4EALDH1A1L3MBTL1AURKA
SCHEMBL31214110 0.73 PDE4B (0.37) KDM4EL3MBTL1HSD17B10GPBAR1
SCHEMBL31022760 0.72 POLB (0.36) KDM4EALDH1A1GAASMN1; SMN2NPSR1
SCHEMBL13500438 0.72 POLB (0.36) KDM4EALDH1A1GAASMN1; SMN2NPSR1
SCHEMBL15201463 0.72 ULK1 (0.39) ULK1KDM4EALDH1A1L3MBTL1GAA
SCHEMBL31214354 0.71 NPSR1 (0.41) KDM4EALDH1A1GAANPSR1
SCHEMBL23674417 0.71 NT5E (0.36) HSD17B10TRPV4
SCHEMBL14612841 0.71 ALOX5AP (0.38) AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 EP disclosed
WO-2024033277-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 WO disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 ULK1 4672/4885S100A9 3164/4885KDM4E 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.